Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 7, 2013, Pages 861-862

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; INCRETIN; INFLAMMASOME; ROSUVASTATIN;

ANGIOGENESIS; ECHOGRAPHY; FAT INTAKE; HUMAN; LETTER; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; FATTY LIVER; HUMANS;

EID: 84879045304     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.811024     Document Type: Letter

References (5)

1. Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets 2013; 17(7): 773-9
2. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83 (Pubitemid 43875555)
3. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805
4. Athyros V.G., Tziomalos K., Gossios T.D., Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the greek atorvastatin and coronary heart disease evaluation (greace) study: A post-hoc analysis. GREACE Study Collaborative Group. Lancet. 2010:376, 1916-1922.
5. Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia. A preliminary report. Curr Vasc Pharmacol 2013; In press